This is the first study of World Health Organization–recommended weekly PQ therapy in Southeast Asia in which changes in the Hb level and other hemolytic markers over time are reported for patients with P. vivax malaria who have moderately severe G6PD deficiency or are G6PD normal. This evidence concerns the gene G6PD and G6PD deficiency.